Watson Pharmaceuticals’ Eden Biodesign, Ltd., has entered a non-exclusive vendor network agreement with Crucell, under which Eden Biodesign becomes an authorized provider of process development and cGMP manufacturing services using Crucell’s PER.C6 cell line technology. Crucell’s human PER.C6 cell line is manufacturing system for high-yield, large-scale production of vaccines, recombinant proteins and gene therapy products. Eden Biodesign will also be able to offer its services to Crucell’s PER.C6 licensees in the field of vaccines and gene therapy.

Eden Biodesign develops and produces of a range of vaccine and gene therapy products derived from diverse virus types. Its cGMP manufacturing facility offers fully segregated viral production at a range of scales, using a various production technologies and processes, including a platform approach for the production of adenoviruses in stirred tank suspension culture.

Crawford Brown, Ph.D., chief executive officer of Eden Biodesign, said, “We are delighted to strengthen our relationship with Crucell and to be able to offer our services to Crucell’s PER.C6 licensees. We have demonstrated that the combination of Crucell’s proven and valuable technology and Eden Biodesign’s expertise in vaccine and gene therapy development and manufacturing delivers tremendous value to our customers by accelerating progression of products into and through clinical development, while maintaining the ability to scale-up production and achieve a highly attractive cost-of-goods.”